Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$22.40 (+1.13%) as of
Key statistics
- Market cap
- 2.37B
- EPS (TTM)
- -1.05
- Dividend yield
- 0.00%
- 52-week range
- 18.00 – 28.90
- Beta
- 0.04
- Revenue (TTM)
- 157.86M
- Profit margin
- -62.74%
- Volume
- 81.38k
About Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.